Ini1/hsnf5 gene encodes INI1 protein, a chromatin remodeling factor associated with the SWI/SNF complex. In yeast, this complex modi®es chromatin condensation to coactivate various transcriptional factors. However, in human, little is known about the SWI/SNF complex and INI1. To elucidate cellular functions of ini1, we constructed a recombinant adenovirus (AdexHA-INI1) capable of overexpressing INI1 in ini1-de®cient cells. AdexHA-INI1 produced intranuclear INI1 in three ini1-de®cient cell lines, changed their morphology, and decreased the proportion of viable cells. Flow cytometry and a BrdU incorporation assay showed that after the infection, growth of these cells was partially arrested at G1. In two of the three ini1-de®cient cell lines, apoptosis was found to occur after the infection, as detected by the presence of cleaved poly (ADP-ribose) polymerase. To determine functional domains of INI1, we constructed plasmids expressing INI1 and its deletion mutants, which were used for a colony formation assay. Repeats 1 and 2 of INI1 were found to be required to suppress the growth of the three ini1-de®cient cell lines. The results support the hypothesis that ini1 is a tumor suppressor gene and suggest a novel link between human SWI/SNF chromatin remodeling complex and apoptosis.
Introduction
Ini1 encodes a nuclear protein that is a member of SWI/SNF chromatin remodeling complex. INI1 (integrase interactor 1) was originally isolated as a cellular protein that speci®cally binds to HIV-1 integrase and shown to be a human SNF5, a member of the human SWI/SNF complex (Kalpana et al., 1994) . The SWI/SNF complex is a 2 mega-dalton (MDa) multiprotein complex that remodels nucleosomes with energy derived from the hydrolysis of ATP (Whitehouse et al., 2000) . In yeast, this complex regulates expression of various genes by modifying the local topology of chromatin that limits the access of transcriptional activators or general transcriptional factors to the speci®c DNA binding domains (Sudarsanam et al., 1999; Sudarsanam and Winston, 2000) . The SWI/SNF complex consists of dierent subunits in species, however, INI1 is a core subunit in human SWI/SNF complex and required for chromatin remodeling activity (Phelan et al., 1999) .
To date, several evidences suggesting the function of ini1 gene have been shown. INI1 has been found to interact not only with HIV-1 integrase but with cellular and viral transactivators including c-Myc (Cheng et al., 1999) , ALL1 (Rozenblatt-Rosen et al., 1998) , Epstein ± Barr virus EBNA2 (Wu et al., 2000) , and human papillomavirus type 18 E1 (Lee et al., 1999) . Furthermore, INI1 was found to be inactivated in a group of pediatric aggressive neoplasms, malignant rhabdoid tumors (MRTs) (Versteege et al., 1998) . However, most of INI1's functions or target genes of human SWI/SNF complex is not shown. To investigate the functions of INI1 gene, we overexpressed INI1 proteins of the wild-type as well as a series of deletion mutants in three ini1-de®cient cell lines, two MRT cell lines and a rhabdomyosarcoma cell line by using adenoviruses and plasmids. multiplicities of infection (MOIs) in ini1-de®cient (G401, KYM-1 and TM87-16) and ini1-intact (HeLa) cells infected with AdexHA-INI1, which carries ini1 gene under the control of strong CAG promoter ( Figure 1a) . In G401 and HeLa cells, the expressed HA-INI1 protein increased as MOIs increased, while it decreased at MOIs higher than 120 and 60, respectively, presumably due to adenovirus cytopathic eect (CPE).
As shown in Figure 1b , INI1-speci®c immuno¯uor-escent signals were detected as spotty precipitates in the nuclei of KYM-1 and HeLa cells infected with AdexHA-INI1. This is compatible to the report that endogeneous INI1 was localized in the nuclei as a member of the SWI/SNF complex (Wang et al., 1996) . It was also reported that HA-tagged INI1 was immunopuri®ed as 2 MDa complex from cells expressing an HA-tagged version of INI1 , suggesting our HA-tagged INI1 protein expressed by adenovirus in the nuclei exists presumably as a member of the SWI/SNF complex.
Morphological changes in ini1-deficient cells infected with AdexHA-INI1
Infection with AdexHA-INI1 changed ini1-de®cient cells morphologically; G401 formed round and shrunk cells (Figure 2d 
Growth inhibition of ini1-deficient cells infected by AdexHA-INI1
The numbers of viable ini1-de®cient cells infected with AdexHA-INI1 were signi®cantly fewer than those infected with AdexLacZ at 72 h post infection ( Figure  3 ). In contrast, the numbers of viable HeLa cells infected at various MOIs with AdexHA-INI1 and AdexLacZ were almost the same, however, they decreased at MOIs higher than 30 as MOIs increased; nonspeci®c adenovirus-induced CPE appeared to occur at MOIs higher than 30 in HeLa cells. In contrast, the numbers of viable ini1-de®cient cells infected with AdexLacZ also decreased as MOIs were increased, presumably by nonspeci®c adenovirus-induced CPE. These results suggested that INI1 protein speci®cally inhibited the growth and/or caused cell death in ini1-de®cient cells.
Induction of G1 arrest in ini1-deficient cells infected with AdexHA-INI1
Sixty hours post infection, ini1-de®cient cells infected with AdexHA-INI1 showed more fraction of G1 phase and less fractions of S and G2 phases than those Figure 4 ). The G1/G2 ratio of the ini1-de®cient cells infected with AdexHA-INI1 was about two times higher than the ratio of those infected with AdexLacZ. In contrast, HeLa cells infected with AdexHA-INI1 and AdexLacZ showed almost similar pro®les of the DNA contents. Table 1 shows the mean pro®les of the DNA contents obtained from three independent experiments. In a BrdU assay to estimate the activity of DNA synthesis, the BrdU incorporation to ini1-de®cient cells infected with AdexHA-INI1 was signi®cantly lower than that with AdexLacZ ( Figure 5 ). In contrast, the BrdU incorporation to HeLa cells infected with AdexLacZ was comparable to that to cells infected with AdexHA-INI1, although they decreased at MOIs higher than 64 in an MOI-dependent manner. Adenovirus-induced CPE presumably inhibited BrdU incorporation at higher MOIs in HeLa cells as well as in ini1-de®cient cells infected with AdexLacZ. These results suggested that the expression of INI1 protein inhibited cellular DNA synthesis speci®cally in ini1-de®cient cells. Together with the results of cell cycle analysis and a BrdU assay, it was suggested that expression of INI1 protein arrested the cell cycle progression at G1 to S phase transition in ini1-de®cient cells.
Induction of apoptosis in ini1-deficient cells infected with AdexHA-INI1
We obtained evidence that expression of INI1 induced apoptosis in KYM-1 and TM87-16 cells following the G1 arrest. First, in ini1-de®cient cells infected with AdexHA-INI1, we observed a number of shrunk and detached cells 60 to 72 h post infection (data not shown). Flow cytometric analysis also showed increase of subG1 fraction, which is characteristic to apoptosis, in KYM-1 and TM87-16 cells infected with AdexHA-INI1 at 72 h post infection ( Figure 6a and Table 1 ). Furthermore, we detected cleaved PARP, which is a marker for the detection of apoptosis (Duriez and Shah, 1997), in KYM-1 and TM87-16 cells infected with AdexHA-INI1 72 h post infection, but not in HeLa and G401 cells infected with either AdexHA-INI1 or AdexLacZ (Figure 6b ). These results suggested that INI1 induced apoptosis in KYM-1 and TM87-16 cells following the induction of G1 arrest.
Inhibition of the colony formation of ini1-deficient cells by expression of the wild-type and mutant forms of INI1
To determine functional domains of INI1 protein for the inhibitory eects on cell growth, we constructed a . These included 3'-deletions (DCC, DRpt1, and DRpt2) and 5'-deletion (DSK). All the mutants as well as the wild-type cDNA were subcloned into pHM6 expression vector, which carries a neomycin (G418)-resistance gene as a selection marker. These plasmids were shown to express HA-tagged truncated INI1 proteins of expected size to a similar extent in HeLa cells 48 h after transfection as estimated by immunoblot analysis (Figure 7b ). Ini1-de®cient cells were transfected with one of these plasmids, and the numbers of G418 resistant colonies were counted.
As shown in Figure 7c , the ini1-de®cient cells transfected with the wild-type or DSK INI1 expression plasmids formed 7 ± 20-fold fewer G418-registant colonies than those transfected with the parental plasmid pHM6. In contrast, ini1-de®cient cells transfected with DRpt1 or DRpt2 formed similar numbers of colonies to the control. Ini1-de®cient cells transfected with DCC showed about 40% inhibition of pHM6.
Furthermore, HeLa cells transfected with any of INI1 expression plasmids formed as many colonies as those transfected with pHM6. These results suggested that INI1 required its conserved C-terminal region including Rpt 1 and Rpt 2 to inhibit the colony formation speci®cally in ini1-de®cient cells.
Discussion
We demonstrated that INI1 induced both growth arrest in G1 phase of the cell cycle and apoptosis when we overexpressed the INI1 protein in three ini1-de®cient cell lines (two MRT cell lines and a rhabdomyosarcoma cell line). Evidence that INI1 arrests cell growth is that adenovirus-mediated introduction of INI1 induced¯at cell morphologies ( Figure  2 ) and inhibited growth of the ini1-de®cient cells in both cell-counting ( Figure 3 ) and colony-formation (Figure 7c ) assays. Evidence that it arrests cell cycle The G1/G2 ratio and fraction of subG1 (%) was calculated by¯ow cytometrical analysis from at least three independent experiments. The numbers show the means+standard errors progression at the G1 phase is that adenovirusmediated introduction of INI1 resulted in increase of G1 fraction and decrease of S and G2 fraction in¯ow cytometric analysis (Figure 4 , Table 1 ) and that it decreased DNA synthesis in BrdU assay ( Figure 5 ). Moreover, we demonstrated that Rpt 1 and 2, highly conserved regions required for interaction with other subunits of the SWI/SNF complex, was responsible for this inhibitory activity (Figure 7c ). Furthermore, expression of ini1 induced increases of subG1 fraction in¯ow cytometric analysis and the production of cleaved PARP in immunoblot analysis, which are speci®c to apoptosis, in two of the three ini1-de®cient cell lines following G1 arrest (Figure 6a ,b, Table 1 ). These experimental results agree with previous genetic analysis in human (Versteege et al., 1998; Biegel et al., 1999; Sevenet et al., 1999) and in mice (Roberts et al., 2000; Klochendler-Yeivin et al., 2000) . Most human samples and cell lines from MRTs showed biallelic inactivating mutations of the ini1 genes. In a mouse model, homozygous knockout of ini1 genes resulted in lethality, whereas heterozygous knockout resulted in progeny that appeared normal. However, beginning as early as 5 weeks of age, most heterozygous mice developed tumors consistent with MRTs (Roberts et al., 2000) . These together suggest ini1 behaves as tumor suppressor.
From several lines of evidence, we hypothesize that human SWI/SNF complex regulates the function of genes involved in cell growth and/or malignant transformation, that is, loss of some components of the SWI/SNF complex is likely to result in its inactivation, leading to formation of tumors. First of all, our data demonstrated that INI1, a component of the SWI/SNF complex, has growth-suppression activities on ini1-de®cient cells. Other component of the SWI/SNF complex, Brg1, was found to be mutated in various human tumors (Wong et al., 2000) . Finally, the SWI/SNF complex was found to interact with c-Fos (Murphy et al., 1999) that is involved in control of cell growth and/or malignant transformation and with BRCA1 (Bochar et al., 2000) that plays a critical role in genome integrity (Brodie and Deng, 2001 ). Therefore, we speculate that overexpression of INI1 in ini1-de®cient cells renders ini1-de®cient SWI/SNF complexes integral, resulting in restoration of growth control pathways regulated by the SWI/SNF complex. In contrast, overexpression of INI1 did not suppress the growth of HeLa cells, because ectopic expression of INI1 may not aect the integrity of the SWI/SNF complex which is originally intact in HeLa cells. It is also noteworthy that the expression of ini1 mutants (DRpt1 and DRpt2) that lack regions required for the interaction with other subunits of the SWI/SNF complex (Muchardt et al., 1995) could not arrest growth of the ini1-de®cient cells (Figure 7 ). This suggests that loss of interaction of components may aect the formation and function of the SWI/SNF complex. How the dysfunction of the SWI/SNF complex leads to aberrant cell growth remains to be investigated. In this direction, we will be able to utilize ini1-de®cient cells and AdexHA-INI1 to pro®le gene expression in those cells with and without expression of INI1 using a DNA microarray system.
Our observations that INI1 induced apoptosis in ini1-de®cient cells suggest the presence of a novel link between chromatin remodeling machinery and cell death. However, ini1's ability to induce apoptosis appeared to vary among cells, since we could not detect the increase of subG1 fraction nor the cleaved PARP in G401 cells infected with AdexHA-INI1 even 72 h after infection ( Figure 6 ). We speculate that the inducibility depends on other genes involved in apoptosis. Our working hypothesis is that G401 cells are also lost such genes that induce apoptosis in the downstream of SWI/SNF complex, since G401 cell line was found to lack numerous genes on chromosome 11 (Garvin et al., 1993) .
The use of ini1 in gene therapy represents an important strategy against the ini1-de®cient tumors (including MRTs) because they are largely incurable due to their high metastatic activity and resistance to current therapies including chemotherapies and radiotherapy (Brand and Covert, 2001) . In this report, we generated a high titer of adenovirus vector expressing functional INI1 protein (Figure 1 ) and empirically demonstrated that ini1 resembles p53 in that it induces both growth inhibition and apoptosis. Consequently, ini1 is an eligible candidate in gene therapy for ini1-de®cient cells, as is the case of p53-gene therapy for p53-de®cient tumors. 
Materials and methods

Cells and antibodies
MRT cell line, G401 (Peebles et al., 1978) was obtained from Japanese Collection of Research Bioresources (JCRB). Another MRT cell line, TM87-16 (Ota et al., 1993) and rhabdomyosarcoma cell line KYM-1 (Sekiguchi et al., 1985) were obtained from Dr Hayashi (Department of Pediatrics, University of Tokyo). A human cervical cell line, HeLa (Scherer et al., 1953) as a ini1-intact cell line, was obtained from JCRB. The levels of INI1 mRNA in these cells were con®rmed by reverse transcription-polymerase chain reaction (RT ± PCR), in which only HeLa cells showed detectable ini1 mRNA. 293 cells (Graham et al., 1977) were obtained from Takara Shuzo Co. Ltd (Kyoto, Japan).
A monoclonal antibody to in¯uenza virus hemagglutinin (HA) (rat, clone 3F10; Roche Molecular Biochemicals, Indianapolis, IN, USA), and a polyclonal antibody to cleaved poly (ADP-ribose) polymerase (PARP) (Cell Signaling Technology, Beverly, MA, USA) were used. Horseradish peroxidase (HRP)-conjugated goat antibodies to rat IgG (ICN Biomedicals, Inc. Aurora, OH, USA) and to rabbit IgG (Cell Signaling Technology) were used.
Recombinant adenoviruses
Using Adenovirus Expression Vector Kit (Takara Shuzo), we constructed recombinant adenoviruses for expressing HAtagged INI1 protein and Escherichia coli û-galactosidase, and termed them AdexHA-INI1 and AdexLacZ, respectively. Viruses were propagated in 293 cells, puri®ed twice by cesium chloride gradient ultracentrifuge, and dialyzed against 10% glycerol in phosphate buered saline (PBS). and (5'-GAGCGGCCGCCAGGCCGGGCCCGTGTTGGC-3') (the HindIII and NotI recognition sequences are underlined). The HindIII ± NotI fragment (1.17 kb) of ini1 cDNA encoding INI1 protein of 385 amino acids (aa) was cloned into pHM6 TM (Roche Molecular Biochemicals) at the HindIII/NotI sites. The resulting plasmid was designated pHM6-INI1 and used for the production of the following deletion mutants. pHM6-INI-DRpt1 and pHM6-INI-DRpt2 were constructed by the use of PCR-based gene splicing by overlap extension (Horton et al., 1989) . The resulting mutants, pHM6-INI-DRpt1 and pHM6-INI-DRpt2, carry deletions of aa 187 ± 245 and 259 ± 319, respectively. The BsaBI ± NotI fragment containing a putative coiled-coil region in the C-terminus was removed from pHM6-INI1 to generate pHM6-INI-DCC carrying a deletion of aa 339 ± 385. The SauI ± KpnI fragment was removed from pHM6-INI1 to generate pHM6-INI-DSK carrying a deletion of aa 120 ± 133.
Immunoblot analysis
For infection, cells were seeded in 12-well culture plates at a density of 1.0610 5 per well. The next day, cells were infected at various multiplicities of infection (MOIs). For transfection, HeLa cells were seeded in a 12-well culture plate at a density of 1.2610 5 per well. The next day, HeLa cells were transfected with 0.8 mg of each of ini1-mutant plasmids by the use of LipofectAMINE PLUS TM (Life Technologies Inc) as instructed by the manufacturer. Fortyeight hours post infection or transfection, cell lysates were prepared and subjected to immunoblot analysis as described (Okui et al., 1998) with a monoclonal antibody to HA (rat, clone 3F10; Roche Molecular Biochemicals, Indianapolis, IN, USA).
For apoptosis detection, 24, 48, and 72 h post infection, cellular proteins were extracted, resolved by SDS ± PAGE (7.5%), and subjected to immunoblot analysis with an antibody to PARP as instructed by manufacturer.
Immunofluorescent staining
Cells were seeded in 8-well culture slides (Becton Dickinson Labware, Bedford, MA, USA) at a density of 3.0610 4 cells per well. The next day cells were infected with AdexHA-INI1 or AdexLacZ at appropriate MOIs. Forty-eight hours post infection, cells were ®xed with 10% buered-Formalin, permealized with PBS containing 0.2% Triton X-100, and stained with an anti-HA-¯uorescein (Roche Molecular Biochemicals, 5 mg/ml).
Cell counting assay
Cells were seeded in a 96-well culture plate at a density of 1.0610 4 cells per well. The next day, cells in triplicate wells were infected with AdexHA-INI1 or AdexLacZ at various MOIs, and incubated in 100 ml/well culture medium. Seventytwo hours post infection, the number of viable cells was estimated with Cell Counting Kit-8, which contains WST-8 (2-(2-methoxy-4-nitrophnyl)-3-(-4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (Wako Pure Chemical) (Kitamura et al., 1999) MOIs. Sixty hours post infection, cells were harvested, ®xed with 75% ethanol at 7208C, and stained with propidium iodide (50 mg/ml) containing RNase A (100 mg/ml) at room temperature for 30 min. Cells were examined with a FACSCalibur¯ow cytometer (Becton Dickinson, Immunocytometry System, Mountain View, CA, USA), and cell cycle was analysed with ModFit LT (version 2) (Verity Software House, Topsham, ME, USA).
Cell proliferation assay
Cells were seeded in a 96-well culture plate at a density of 2.0610 3 cells per well. The next day, cells in triplicate wells were infected with AdexHA-INI1 or AdexLacZ at various MOIs, and incubated in 100 ml/well culture medium. Fortyeight hours post infection, cells were labeled for 2 h with BrdU. BrdU incorporated into cellular DNA was quanti®ed with Cell Proliferation ELISA, BrdU (colorimetric) (Roche Molecular Biochemicals), as instructed by the manufacturer.
Colony formation assays
Cells were seeded in a 24-well culture plate at a density of 1.0610 5 per well. The next day, cells were transfected with 0.4 mg of one of INI1-expression plasmids with LipofectAMINE PLUS TM (Life Technologies Inc) according to the manufacturer's instructions. Forty-eight hours post transfection, cells were trypsinized, split at a dilution of 1 : 5 into 100 mm dishes in duplicate, and cultured in the presence of G418 at a concentration of 0.4, 0.4, 0.8 or 1.0 mg/ml for G401, TM87-16, KYM-1 or HeLa cells, respectively. Fourteen days after selection, cells were ®xed with 10% buered-formalin and stained with 0.1% crystal violet. Colonies with diameters over 1.0 mm were counted.
Abbreviations MRT, malignant rhabdoid tumor; PARP, poly (ADPribose) polymerase; MOI, multiplicity of infection; CPE, cytopathic eect.
